Navigation Links
Octapharma Receives Orphan Drug Exclusivity Approval for wilate(R) - A Replacement Therapy Developed Specifically for von Willebrand Disease
Date:1/13/2010

y growing U.S. division of Octapharma AG

"The FDA orphan drug exclusivity approval for wilate® is an important aspect in Octapharma`s development of this drug," said Kim Bjornstrup, Vice Chairman Octapharma Group. "Orphan drug exclusivity confirms Octapharma's decision to focus exclusively on the treatment of von Willebrand patients. Wilate has a combination of two viral attenuation steps, high purity and a physiological 1:1 ratio of VWF and FVIII activity and is approved for treating all VWD patients including those with the most severe, type 3, disease."

About wilate®:

Wilate® is a newly developed, high-purity, double virus inactivated von Willebrand Factor/Coagulation Factor VIII Concentrate (Human) that demonstrated efficacy for all types of VWD including pediatric patients in four prospective clinical trials utilizing both objective and subjective criteria.

On December 4, 2009, wilate® received FDA approval for the treatment of spontaneous and trauma-induced bleeding episodes in patients with severe VWD as well as patients with mild or moderate VWD in whom the use of desmopressin is known or suspected to be ineffective or contraindicated.(1) Wilate® is the first double virus inactivated VWF/FVIII (von Willebrand Factor/Factor FVIII), high-purity concentrate, utilizing the solvent/detergent (S/D) process and a special terminal dry-heating (TDH) system. The selected purification processes isolate the VWF/FVIII complex under highly protein-protecting conditions, resulting in a 1:1 ratio of VWF:RCo (ristocetin cofactor) and FVIII activities that is similar to normal plasma. Wilate® is exclusively derived from large pools of human pl
'/>"/>

SOURCE Octapharma AG
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease
2. Octapharma Group and Fresenius Kabi Enter Into an Exclusive License, Development and Supply Agreement for a HESylated Recombinant Protein
3. Octapharma Targeting the Major Risk of Hemophilia Treatment - FVIII Antibodies
4. Octapharma Accepting Applications for Research Grants on Immunotherapy, Coagulation Disorders and Critical Care
5. Plasma Products Safe Despite Swine Influenza Outbreak, Assures International Biopharmaceutical Company Octapharma
6. Tianyin Pharmaceutical Co., Inc. Receives Chinese SFDA Approval for Ofloxacin and Fleroxacin
7. GeneGo Receives SBIR Grant
8. WorldHeart Receives Unconditional BTT Study Approval From FDA for Levacor(TM) VAD
9. VIA Pharmaceuticals Receives Delisting Notification From NASDAQ
10. KV Pharmaceutical Receives Permission from NYSE for its Securities to Continue Trading on the NYSE until March 31, 2010
11. AdvanDx Receives FDA 510(k) Clearance for 90 Minutes PNA FISH(R) Protocol for Identifying Gram-Negative Bloodstream Pathogens
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... KONG and FT LAUDERDALE, Florida ... Inc. ("OrbusNeich"), a designer, developer, manufacturer and marketer of innovative ... that on May 13, 2015, it prevailed in a final ... European Patent EP 1 341 482 - STENT HAVING HELICAL ... of review in the EPO and has been upheld as ...
(Date:7/1/2015)... , July 1, 2015  Imprimis Pharmaceuticals, Inc. ... on the development and commercialization of proprietary compounded ... ring The Nasdaq stock market closing bell on ... growing success of its Go Dropless™ campaign since ... cataract procedures are performed annually in the U.S. ...
(Date:7/1/2015)...  LabStyle Innovations Corp. (DRIO), developer of the ... of Todd Durniak as Senior Vice President and General ... over 20 years of medical device commercial and ... and General Manager of Neighborhood Diabetes, a division ... durable medical equipment (DME) and pharmacy channels with ...
Breaking Medicine Technology:OrbusNeich Announces Favorable Ruling from the European Patent Office and Initiation of Litigation Against Terumo Corporation 2Imprimis Pharmaceuticals to Ring The Nasdaq Stock Market Closing Bell 2Imprimis Pharmaceuticals to Ring The Nasdaq Stock Market Closing Bell 3Imprimis Pharmaceuticals to Ring The Nasdaq Stock Market Closing Bell 4LabStyle Innovations Appoints Senior VP & General Manager in U.S. for the Dario Diabetes Management Solution 2LabStyle Innovations Appoints Senior VP & General Manager in U.S. for the Dario Diabetes Management Solution 3LabStyle Innovations Appoints Senior VP & General Manager in U.S. for the Dario Diabetes Management Solution 4
... SILVER SPRING, Md., Oct. 7, 2011 The U.S. ... simvastatin), a fixed-dose combination (FDC) prescription medication that contains ... in adults who need both sitagliptin and simvastatin. ... million people in the United States have type 2 ...
... Oct. 7, 2011 ProteinSimple today announced plans ... service support for its biologics products in Europe, ... are included in this expanded support structure:  iCE ... systems. The biologics market segment is ...
Cached Medicine Technology:FDA Approves Combination Therapy Juvisync 2FDA Approves Combination Therapy Juvisync 3ProteinSimple to Offer Direct Sales, Service and Support for Biologics Products in Europe 2
(Date:7/1/2015)... (PRWEB) , ... July 01, 2015 , ... ... technology and services, today announced that its fifth annual Smile for a Lifetime ... $80,000 for the non-profit organization. In addition to supporting S4L in its mission ...
(Date:7/1/2015)... VA (PRWEB) , ... July 01, 2015 , ... Dr. ... on Monday, July 6th on WAVY-TV’s The Hampton Roads Show to discuss non-invasive ... where diet and exercise fall short. , CoolSculpting fat reduction utilizes Cryolipolysis to ...
(Date:7/1/2015)... NJ (PRWEB) , ... July 01, 2015 , ... ... , the global cancer enterprise of Hospital Corporation of America (HCA), as it ... and research, OncLive announced today. , With this new partnership, OncLive’s editorial ...
(Date:7/1/2015)... (PRWEB) , ... July 01, 2015 , ... Did you ... June is Men’s Health Month, and we at Advanced Fertility Center of Texas (AFCT) ... in men. , While infertility is often considered to be a “woman’s issue,” ...
(Date:7/1/2015)... ... ... As if mood swings, cramps and child labor weren’t enough to endure, there ... Houston Vein Center is offering tips on the treatment options for women with leg ... often overlooked. Many women experience the tiredness, achiness, restless legs, cramps and itchiness related ...
Breaking Medicine News(10 mins):Health News:The Forum Fundraiser Raises $80,000 for the Smile for a Lifetime Foundation 2Health News:The Forum Fundraiser Raises $80,000 for the Smile for a Lifetime Foundation 3Health News:Dr. Surya Challa of Chesapeake Vein Center and MedSpa Will be Featured on The Hampton Roads Show on WAVY-TV 2Health News:Dr. Surya Challa of Chesapeake Vein Center and MedSpa Will be Featured on The Hampton Roads Show on WAVY-TV 3Health News:OncLive® Welcomes Sarah Cannon Cancer Network to Its Strategic Alliance Partnership Program 2Health News:OncLive® Welcomes Sarah Cannon Cancer Network to Its Strategic Alliance Partnership Program 3Health News:Male Fertility: Improve Testosterone and Fertility With Natural Approaches 2Health News:Male Fertility: Improve Testosterone and Fertility With Natural Approaches 3Health News:Male Fertility: Improve Testosterone and Fertility With Natural Approaches 4Health News:Northeast Houston Vein Center Offers Tips for Women with Leg Pain 2Health News:Northeast Houston Vein Center Offers Tips for Women with Leg Pain 3
... is here, so the Hispanic "got,milk?" campaign is declaring it ... the "sunshine vitamin." , Even though ... when the,ultraviolet rays of the sun hit our skin, many ... deficiency in this country is being called a,silent epidemic. The ...
... March 26 Today, in Roach v. Stouffer ... Missouri officials acted unconstitutionally when they denied a valid ... its pro-life viewpoint. The court also ordered the ... CEO, stated, "It is encouraging that more and more ...
... pleaded guilty today in connection with a $10 million ... Attorney General Rita M. Glavin of the Criminal Division ... District of Florida announced. Dr. Carmen Del Cueto, 65, ... count of conspiracy to commit health care fraud before ...
... First community hospital to offer comprehensive genomic medicine ... DNA DirectMOUNTAIN VIEW, Calif. and SAN FRANCISCO, March ... Silicon Valley, and DNA Direct, a provider of ... launched the Genomic Medicine Institute (GMI), becoming the ...
... causes many tumbles, CDC reports, , , THURSDAY, March 26 (HealthDay ... many Americans, but they,re also apparently the cause of falls ... health officials report that 86,629 people annually are injured in ... wind up in hospital emergency rooms, according to the U.S. ...
... ALTO, Calif., March 26 Jazz Pharmaceuticals, Inc. (Nasdaq: ... quarter and full year ended December 31, 2008. Total revenues ... compared to $15.5 million for the quarter ended December 31, ... were $67.5 million, compared to $65.3 million for the year ...
Cached Medicine News:Health News:Vitamin D Deficiency Has Emerged as a Silent Epidemic 2Health News:Vitamin D Deficiency Has Emerged as a Silent Epidemic 3Health News:Americans United for Life Applauds Ruling Directing Missouri to Issue 'Choose Life' Plate 2Health News:Miami Doctor and Chemist Plead Guilty in HIV Infusion Fraud Scheme 2Health News:Miami Doctor and Chemist Plead Guilty in HIV Infusion Fraud Scheme 3Health News:El Camino Hospital Launches Genomic Medicine Institute 2Health News:El Camino Hospital Launches Genomic Medicine Institute 3Health News:El Camino Hospital Launches Genomic Medicine Institute 4Health News:For All Their Plusses, Pets Pose a Risk for Falls, Too 2Health News:For All Their Plusses, Pets Pose a Risk for Falls, Too 3Health News:Jazz Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2008 Financial Results 2Health News:Jazz Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2008 Financial Results 3Health News:Jazz Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2008 Financial Results 4Health News:Jazz Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2008 Financial Results 5Health News:Jazz Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2008 Financial Results 6Health News:Jazz Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2008 Financial Results 7Health News:Jazz Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2008 Financial Results 8
Inquire...
Inquire...
... anti-reflux valve is enclosed in ... prevents the valve from being ... sitting or reclining positions. The ... interference free ensuring uninterrupted flow ...
... valve is enclosed in a ... the valve from being accidentally ... or reclining positions. The valve ... free ensuring uninterrupted flow and ...
Medicine Products: